Sector Focus – Healthcare

The healthcare sector is in a state of long-term change, with the COVID pandemic materially impacting the global economy and healthcare delivery and placing the industry under the spotlight.

After something of a pause in the early stages of the pandemic, healthcare M&A activity resumed strongly in 2021 and is continuing through 2022.

The accelerated rollout of telehealth and virtual care is likely to continue to impact business models as legacy players look to adapt their operations. Digital transformation is likely to play a key role in the efficient and effective delivery of post-pandemic care. Other likely areas of growth include mental health, independent living and vaccines/therapeutics.

Stronger organisations are expected to consolidate underperforming players with roll-ups potentially focusing on fragmented sectors such as aged care, disability, primary and allied healthcare.
Healthcare will remain a key sector for private equity investment as a defensive industry, with PE also providing a funding channel for companies facing tightening lending conditions.

Examples of Healthcare transactions we have led include:

Healthcare

  • Advised Potential(x) on its merger/sale to Beamtree Ltd
  • Advised BCAL Diagnostics on IPO and ongoing strategic options
  • Advised e3D Pharma on private capital raise
  • Advised Uprise on sale to IBH Population Health Solutions (now Uprise Health)
  • Advised BCAL Diagnostics on pre-IPO capital raise
  • Advised CannaPacific on capital raise
  • Advised Murdoch Childrens Research Institute on valuation and commercial issues
  • Advised HammondCare on commercial scoping studies and M&A opportunities
  • Advised Model Answers on sale to Parexel
  • Advised IHH Healthcare on bid for large Australian healthcare target
  • Advised HealthcareLink on capital raise from Novita Limited
  • Advised HealthcareLink on acquisition of Newly
  • Advised RT Health Fund on acquisition of Transport Health
  • Advised Safe Work Laboratories on capital raise and majority sale to Pathology Asia Holdings (owned by TPG)
  • Advised HealthcareLink on capital raise
  • Advised Global pharma group on bid for iNova